PCSK9 and metabolic dysfunction-associated steatohepatitis: Recognition of the complex effects of PCSK9 are leading toward a broader use of PCSK9 inhibitors in diseases such as NAFLD and NASH (Ajam et al., 2017; Dimakopoulou et al., 2018).